In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

BioNTech’s willingness to significantly increase its upfront bet on BNT327 reflects a belief the candidate could set a new ...

Vibostolimab/Keytruda regimen did not improve overall survival compared to Tecentriq in extensive-stage SCLC patients. Median ...

high risk early stage TNBC before surgery. After surgery, Keytruda is continued as a treatment by itself, without chemotherapy. Colon cancer and other solid tumors: Keytruda is used for colon ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Cancer drug dealmaking is heating up around ... addressed by the pharmaceutical giant’s blockbuster immunotherapy, Keytruda. Now Merck is joining in with a $588 million deal of its own.

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

Keytruda, a drug for different cancer indications, generates by far the most revenue, more than half of the company’s total revenue. And those sales keep on increasing year-over-year.

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose ...

Merck & Co. has bought into the kind of drug that has emerged as a top threat to its dominant cancer immunotherapy Keytruda. The company said Thursday it agreed to pay privately-held LaNova ...